Savara hunts cash af­ter dou­bling down on late-stage res­pi­ra­to­ry drugs

Austin-based Savara Ther­a­peu­tics got start­ed in biotech with a list of an­gel in­vestors and a lead pro­gram that looked to de­vel­op an in­haled dry pow­der for­mu­la­tion of van­comycin for cys­tic fi­bro­sis suf­fer­ers. Now, with its Phase III loom­ing at the end of the year, the com­pa­ny has lined up an­oth­er late-stage ther­a­py, pick­ing up the res­pi­ra­to­ry as­sets of Dan­ish biotech Seren­dex in an ac­qui­si­tion as it hunts up fresh mil­lions to do a con­sid­er­able amount of de­vel­op­ment work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.